epigallocatechin gallate has been researched along with Diabetic Retinopathy in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Du, J; Guo, Y; Liu, X; Qin, X; Song, E; Sun, X; Tu, Y; Wang, L; Wang, Y; Xu, X; Zhu, M | 1 |
| Liang, S; Zhang, L; Zhang, ZK | 1 |
| Ahmedna, M; Sampath, C; Sang, S | 1 |
3 other study(ies) available for epigallocatechin gallate and Diabetic Retinopathy
| Article | Year |
|---|---|
A prodrug of epigallocatechin-3-gallate alleviates high glucose-induced pro-angiogenic factor production by inhibiting the ROS/TXNIP/NLRP3 inflammasome axis in retinal Müller cells.
Topics: Angiogenesis Inducing Agents; Animals; Blotting, Western; Carrier Proteins; Catechin; Cell Count; Cell Proliferation; Diabetic Retinopathy; Enzyme-Linked Immunosorbent Assay; Ependymoglial Cells; Glucose; Inflammasomes; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Prodrugs; Reactive Oxygen Species; Sincalide; Superoxide Dismutase; Thioredoxins; Transfection | 2020 |
Epigallocatechin-3-gallate protects retinal vascular endothelial cells from high glucose stress in vitro via the MAPK/ERK-VEGF pathway.
Topics: Apoptosis; Blindness; Catechin; Cell Cycle; Diabetic Retinopathy; Endothelial Cells; Flow Cytometry; Gene Expression Regulation; Glucose; Humans; Intercellular Adhesion Molecule-1; Interleukin-6; MAP Kinase Signaling System; NF-kappa B; Retina; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2016 |
In vitro and in vivo inhibition of aldose reductase and advanced glycation end products by phloretin, epigallocatechin 3-gallate and [6]-gingerol.
Topics: Aldehyde Reductase; Animals; Biomarkers; Blood Glucose; Catechin; Catechols; Cell Line; Cell Survival; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Diet, High-Fat; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fatty Alcohols; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Kidney; Kinetics; Male; Mice, Inbred C57BL; Myocardium; Phloretin; Retinal Pigment Epithelium; Time Factors | 2016 |